BCR and B-cell chronic lymphocytic leukemia: These studies suggests that a low level of FOXO1 activity, possibly promoted through tonic BCR signalling, sustains CLL cell survival, while higher FOXO1 activity induced by inhibition of upstream PI3K/AKT signals through drug treatment triggers CLL cell death (106, 108).